Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep I think it's because the Canadian exchange tickers never have active chatter boards lol
This is 1 of my only green mj plays today lol
sleeper stock.
Incredibly quiet board .
Great to see Abcann in a new publication.
Yup great stock....... any guru here to provide TA? Thx
Saw some ABCN product and it was absolutely chunky smelly dank goodness. They definitely know how to grow :)
Medical Cannabis Supplier ABcann Global Corp. (TSX.V: $ABCN) (OTCQB: $ABCCF) Keeps Pricing Competitive
http://theseedinvestor.com/cannabis-news/Medical-Cannabis-Supplier-ABcann-Global-Corp-Keeps-Pricing-Competitive
People realized this is way too low compared to the other players. We should be at $2.50
Swung by their location in Napanee a few weeks ago. Time will tell!
got some starter will add if it dips to .90-1 dollar again, looking for at least a double by july
This company featured in Equadia Letter yesterday.
www.equedia.com/proof-money-grows-on-trees/?utm_source=November+2017+ABcann+Update&utm_campaign=November+2017&utm_medium=email
The swings in price here are insane and flippers dream!!
ABCN Targets Global Cannabis Market
As a licensed producer under the Marijuana for Medical Purposes Regulations in Canada, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sells cannabis through its ABcann Medicinals, Inc. subsidiary. “We’re now, hopefully, going to be a global presence,” director Aaron Keay said in an interview with CannabisFN (CFN Media). An article discussing this reads: “ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://nnw.fm/0SwRs). The company sells in its Canadian domestic market through its subsidiary, ABcann Medicinals, Inc.”
To view the full article, visit http://nnw.fm/Z60nx
About ABcann Global Corporation
ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. For more information, visit www.ABcannGlobal.com.
Health Canada to receive bulk of federal government's funding for marijuana legalization http://business.financialpost.com/business/health-canada-to-receive-bulk-of-federal-governments-funding-for-marijuana-legalization/
Article of ABCANN breaking ground. Get ready for the lift off.
http://www.napaneebeaver.ca/2017/10/13/abcann-breaks-ground-on-40-million-expansion/
Did you dump at 1.25 n buy back or did you ride the slide?
ABCN Scales Up in Preparation for Canada’s Impending 2018 Recreational Cannabis Legalization
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was one of the first companies to obtain a cannabis production license in Canada, and it continues going strong among the country’s limited number of licensed growers—only 62 to date. The company’s high-tech indoor growing environment—with every facet of the growing, curing and harvesting process controlled and monitored by computer—yields a high-quality product that is clean, steady and repeatable—something the company can effectively leverage should recreational cannabis legalization go through in 2018. An article discussing this reads: “Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology, ABcann has been making strategic strides in recent months. The company recently announced the receipt of $11.9 million in proceeds from the exercise of warrants. Combined with a previous investment from Cannabis Wheaton Income Corp., this brought ABcann’s cash position to about $45 million, and, in the coming months, the company intends to deploy capital toward expanding its existing Vanluven facility and in developing and constructing its new Kimmett facility. The company will further pursue international expansion plans.”
To view the full article, visit http://nnw.fm/PpcL8
About ABcann Global Corporation
ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. For more information, visit www.ABcannGlobal.com
I started my position on $ABCN and when I discovered massive short position on $CBW bringing down $ABCN I started loading big time on both $ABCN and $CBW so far it has paid off ...got in $ABCN at $.85 and it's now at $1.25. ABCN is heading straight to $2.50 IMO.
As long as we get support!!
Yea... one hell of a swing!!!
Hope it pops again n holds tomorrow/this week.?.?
Aggressive day trading to account for today's wild price swing??
Nope because chuck rifici is a douche
Yup that's exactly right!
Has anyone else considered buying Cannabis Wheaton on the idea that as Abcann goes up, it should go up too??
I think we could see $1.50 - $1.75 US by the end of this week!
ABCCF(ABCN) is on the move. Lets get this to 1.25 U.S.
ABCN Scaling Up to Meet Impending Spike in Cannabis Demand
Ever at the forefront of Canada’s cannabis market, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was among the very first companies to obtain a cannabis production license in that country and has since been working to change the face of medical cannabis—both in Canada and globally. ABcann’s group of companies is working toward the aim of becoming the first cannabis pioneers to produce repeatable, standardized, plant-based medicines around the world.
Every variable of ABcann’s cannabis growing, curing and harvesting process is computer-monitored and controlled. This high-tech indoor growing environment consistently yields a superior product that is clean, steady and repeatable—something desired by every doctor and patient.
Though medical marijuana has been nationally legal in Canada since 2001, the requirements and process for growers to obtain licenses are very stringent, resulting in only about three percent of applying cannabis growers successfully obtaining a license. Canada’s government is also now working toward federally legalizing recreational marijuana, and, as discussed in a recent article (http://nnw.fm/dzT44), this push, coupled with the dearth of licensed growers, could eventuate in a nationwide cannabis shortage as production fails to keep pace with demand. ABcann is scaling up its operations in anticipation of this supply dearth.
There are currently, according to data from the Government of Canada (http://nnw.fm/L7yXs), only 62 licensed cannabis growers in the entire country. With blanket legalization looming on the horizon, demand is sure to increase, and ABcann is well-positioned to profit.
Focused on scaling its operations and distinguishing itself through its proprietary organic and pesticide-free growing technology, ABcann has been making strategic strides in recent months. The company recently announced the receipt of $11.9 million in proceeds from the exercise of warrants. Combined with a previous investment from Cannabis Wheaton Income Corp., this brought ABcann’s cash position to about $45 million, and, in the coming months, the company intends to deploy capital toward expanding its existing Vanluven facility and in developing and constructing its new Kimmett facility. The company will further pursue international expansion plans.
Led by an experienced management team and advisory board, ABcann boasts an impressive production yield that has put it at the vanguard of this highly competitive market.
For more information, visit the company’s website at www.ABcann.ca
Nicely positioned for a major run.
Are the shorts getting squeezed do you think? I tried warning folks shorting to cover this but they didn't listen! I'm up over %25 thank you
$ABCN Canada's Licenced Producers of Medical Cannabis Form Retail Cooperative: Canadian Cannabis Co-op will provide investment, jobs and safe, regulated cannabis to Alberta and beyond!!!
http://theseedinvestor.com/cannabis-news/canada-s-licenced-producers-of-medical-cannabis-form-retail-cooperative-canadian-cannabis-co-op-will-provide-investment-jobs-and-safe-regulated-cannabis-to-alberta-and-beyond
With staggering $142 billion over the next 15 years I'm confident that I'll retire early before 65 that is if I keep this in my diversified portfolio IMO
The Generational Growth Opportunity for Canadian Cannabis
NetworkNewsWire Editorial Coverage: The medical cannabis business is booming in Canada, projected to ramp up and exceed $8 billion within seven years. The growth trajectory shows no signs of slowing yet pales in comparison to the global opportunity. A recent analysis by Eight Capital, a Toronto-based investment bank, targets the potential Canadian international medical cannabis market at a staggering $142 billion over the next 15 years (http://nnw.fm/aFP0h). Licensed producers in good standing are best positioned to reap immense rewards from this generational growth opportunity. Of these, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) (ABcann Profile), among Canada’s first licensed producers, is already considered one of its premiere growers. Others vying for position include OrganiGram Holdings, Inc. (OGRMF), Supreme Pharmaceuticals, Inc. (SPRWF), Maricann Group, Inc. (MRRCF) and iAnthus Capital Holdings, Inc. (ITHUF).
With strict laws enacted in 2016, Health Canada now oversees the licensing process, monitoring and compliance of commercial medical cannabis producers. Licenses are difficult to acquire and frequent inspections hold producers to stringent standards. Health Canada now conducts thorough reviews of applications to ensure compliance with regulations and closely monitors licensed producers to ensure compliance with such strictures as personnel security measures, good production practices, packaging, shipping, record keeping, and importantly, import and export requirements. Global demand, especially in Germany, is growing at an “insane” rate.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sees Germany as a gateway to vast European and global opportunities. “We’re absolutely at the forefront,” recent CEO Aaron Keay told Marijuana Business Daily. “We look at Europe as a significant part of our strategic plans for expansion, in addition to what we’re doing domestically.” Keay, now focused on global operations, confirmed that ABcann expects to acquire a distribution license and start exporting to Germany in the third quarter.
Meticulous specifications in the production of its pharmaceutical grade, plant-based medicines positions ABcann at the vanguard of Canadian global exporters of medical cannabis products. ABcann’s modular approach to systems technology eliminates scale-up risk and enables ABcann to expand anywhere in the world and still maintain consistency and quality of product. Maintaining standards designed to exceed Canadian government requirements, ABcann Medicinals grows plants only in small batches to create controllable, consistent and predictable yields. The plants are nurtured in controlled environmental chambers to deliver repeatedly dependable results with each harvest. Chemical and pesticide free, ABcann produces medical cannabis that effectuates the same pharmaceutical response with each use. Such quality and consistency are prerequisites for importers of medicinal cannabis, especially in Germany that reimburses medical cannabis under its national health system.
In a testament to consistency, quality and immense global opportunity, Cannabis Wheaton, which invests in and supports a wide range of cannabis cultivation companies, announced in a June 2 press release a $30 million investment into ABcann for current operations and expansion to a 130,000-square-foot facility (http://nnw.fm/CHBi5). Cannabis Wheaton further committed to fully fund, with certain conditions, the construction of an additional 50,000 square feet of ABcann’s Kimmett Facility. The 180,000 square feet of funded production capacity places ABcann among the top of all licensed producers. The $30 million investment is being made in two tranches each at C$2.25 per share. The pricing represents a significant premium to the current price of $0.78 US (about C$1.00) per share.
With a market capitalization around $82 million, ABcann presents great value for Cannabis Wheaton and should be on the radar of investors in this space. Other Canadian licensed producers carry much higher market valuations. Even at a C$2.25 per share valuation (about $180 million US market cap) ABcann still represents a compelling value in the industry with many licensed producers commanding valuations two to four times higher.
One such company carrying such a lofty market valuation is OrganiGram Holdings (OGRMF). With a market cap in excess of $233 million, OrganiGram will have over 220,000 square feet of medical cannabis production space at full build out. Even though its a federally licensed producer, OrganiGram was caught up in two Health Canada recalls of almost all its products sold in 2016 after residual levels of two banned pesticides, myclobutanil and bifenazate, were found and company’s organic certification was suspended until compliance to requirements was demonstrated. Health Canada released a public recall of all products produced between February 1, 2016, and December 16, 2016, which included both dried marijuana and cannabis oil. OrganiGram took remedial measures to rectify the problems, is now back in business after losing a year’s revenues and still carries a $230+ million valuation.
Supreme Pharmaceuticals (SPRWF) has a hefty market cap of around $250 million and is trying to become a leading supplier of affordable medical cannabis by applying commercial agriculture practices to medical cannabis production. Supreme Pharmaceuticals expects to produce 10,000 kilograms of cannabis in 2017, with an estimated value of $35 million. At the end of 2016, the company raised $55 million through a convertible debenture that pays investors 10% annually until maturity in January 2019, at which point the lenders can convert into equity at $1.30 per share which may prove quite dilutive.
Licensed in 2014 and with first sales in 2015, Maricann Group (MRRCF) is now expanding its cultivation, extraction, analytics and production facilities for growth into the adult-use cannabis market in Canada, and longer term, into mature and developing cannabis markets worldwide. In August the company reported Q2 sales declined by 27% from previous year levels and down 42% compared to Q1. Lacking environmental controls, Maricann attributed the shortfall to a March windstorm that allowed sand to enter its greenhouses and ultimately caused destruction of all impacted plants.
With a different approach and no licensed Canadian producers, iAnthus Capital Holdings (ITHUF), through its wholly owned subsidiary iAnthus Capital Management, LLC, offers investors diversified exposure to licensed cannabis cultivators, processors and dispensaries in the United States. iAnthus currently owns, operates or has partnered with marijuana license holders in Massachusetts, Vermont, Colorado and New Mexico. Founded by entrepreneurs with experience in investment banking, corporate finance, law and healthcare services, iAnthus provides a combination of capital and operating and management expertise for its companies. The diversification, while limiting downside in the space, severely constricts upside potential and is reflected in the paltry $36 million market valuation.
Canadian medical cannabis companies are uniquely primed and positioned to tap a generational global growth opportunity. Well-capitalized and largely free from competition, Canadian licensed producers are set to gain a first-mover advantage in new international markets as more and more countries legalize marijuana for medical use. Fortunes will be made as international medical cannabis markets balloon to $142+ billion over the next 15 years. To maximize profits in this space, investors should have direct exposure to licensed Canadian medical cannabis producers.
For more information on ABcann Global please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
$ABCN The consumption of extracted oil and oil-based products is predicted to increase 198,000% over the next five years.
https://www.biv.com/article/2017/10/licensing-cannabis-oil-lags-behind-heady-growth/
Demand Outpacing Supply as Canadian Cannabis Legalization Looms
NetworkNewsWire Editorial Coverage: The Canadian government’s plan to push through legalization of marijuana for recreational purposes by mid-2018 figures to deal a serious blow to the existing black market. However, industry analysts are increasingly skeptical of the ability of the country’s Licensed Producers to keep pace with this forecast spike in demand. As noted in a recent article published by CBC, “Unless something changes quickly, the supply of available pot come legalization next July, will be inadequate, and the black market will continue to thrive.” ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN) (ABCCF Profile), with its healthy cash position and aggressive expansion plans, is one company seeking to address these supply concerns, particularly in the medicinal market. Joined in the space by Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED), Aurora Cannabis, Inc. (OTCQX: ACBFF) (TSX: ACB), Aphria, Inc. (OTCQB: APHQF) (TSX: APH) and Medical Marijuana, Inc. (OTC: MJNA), ABcann’s relatively low market cap and beefy portfolio of pharmaceutical-grade IP have it on the radar of investors looking to capitalize on Canada’s much-anticipated “green” revolution.
Mere months out from its initial public offering, ABcann Global Corp. (OTCQB: ABCCF) (TSX.V: ABCN) has already shown tremendous potential in setting itself apart from other Canadian growers. The backbone of the company’s operations, which focus on the development of consistent pharmaceutical-grade products that are organically grown and pesticide-free, is its proprietary growing technology. As noted on its website, ABcann’s products are always free of chemicals and produced in small batches to ensure high quality standards. This commitment to quality has helped ABcann steer clear of the recent wave of product recalls in the Canadian cannabis market that has affected many of the industry’s biggest names.
Scaling these operations has become a major focus for ABcann’s management team in recent months, as highlighted by the company’s latest strategic moves. In mid-September, ABcann announced its reception of $11.9 million in total proceeds from the exercise of warrants. When combined with an earlier investment from cannabis streaming company Cannabis Wheaton Income Corp., the infusion brought ABcann’s cash position to approximately $45 million. As Aaron Keay, director of ABcann, noted in that news release, “The Company’s main focus in the coming months will be on the deployment of capital towards the expansion of [its] existing Vanluven facility and development and construction of the new Kimmett facility, as well as the pursuit of [its] international expansion plans.” These facilities mark another upside of ABcann’s business model, as the company owns the land it intends to use for these expansion projects, eliminating potentially costly leasing expenses.
Supported by a strong management team and guided by an experienced advisory board featuring the “Father of Cannabis Research” Dr. Raphael Mechoulam, ABcann’s favorable production yields place it at the forefront of an extremely competitive market. In its corporate presentation, ABcann compares its yields with industry averages based on PI Financial estimates. Cannabis industry mainstay Canopy Growth Corp.’s (OTC: TWMJF) (TSX: WEED) indoor yield per square foot is estimated at roughly 100 grams. Comparatively, ABcann’s indoor yield clocks in at nearly 350 grams per square foot, and the company is targeting further refinements that could support yields in excess of 425 grams per square foot in the near future, far outpacing industry averages.
PI Financial, in a May 2017 report, provided some insight into the potential upside offered by ABcann’s proprietary growing techniques as the Canadian cannabis market enters its latest boom period. The analyst firm notes that ABcann is currently on course to reach breakeven as soon as the second quarter of 2018, with a ramp up in sales to $74.2 million forecast for fiscal 2019. These projections came alongside a ‘Buy’ rating and a 12-month price target of C$2.25 for ABcann’s Canada-listed shares, which were trading at C$0.96 as of close of market on September 29.
Promising research reports aside, ABcann’s recent efforts to address the expected shortfall in Canadian cannabis supply place it at the forefront of the blossoming industry. Its strong cash position is being used to both expand its fully-operational Vanluven facility and continue construction of its 150,000-square-foot Kimmett facility. As noted in a July news release, ABcann expects first cultivation from the Kimmett facility in the fourth quarter of 2018, with the project reaching full production capacity by the first quarter of 2019. With this expansion, the company will look to expand on its position in the Canadian market while pursuing a number of global initiatives in Europe, Israel and Australia. “We expect that the increase in production capacity will enable ABcann to increase the sales of our premium, organically grown, pesticide free cannabis products in the current domestic market and position the Company for global distribution in the emerging markets we have targeted,” Keay noted in an August update. “Further, the ability to serve larger and broader markets as a result of the production increase positions ABcann extremely well for the anticipated adult consumer market in July 2018.”
ABcann is joined in the Canadian cannabis sector by a number of companies exploring expansion options of their own. Canopy Growth Corp., widely-recognized as Canada’s first $1 billion weed company, operates a number of core cannabis brands targeting both medicinal and recreational markets. Perhaps most notable in this brand portfolio is Tweed, which Canopy calls “the most recognized marijuana production brand in the world” on its website. The production capacity of the Tweed brand highlights the massive market potential of ABcann’s current construction efforts. Per the Canopy Growth Corp. website, Tweed currently maintains roughly 168,000 square feet of licensed production space, and its campus located at the former Hershey Chocolate factory has about 500,000 square feet of available space for expansion. In other words, ABcann’s 150,000-square-foot Kimmett facility, upon completion, will see the company’s production space surpass one of the world’s most notable cannabis brands, and its superior yields should push ABcann’s production figures well beyond the current limits of Canopy’s flagship label.
Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB), on the other hand, had already set its sights on the forecast supply dearth expected to hit the Canadian market in the coming months. In November 2016, Aurora announced the start of construction on an unprecedented 800,000-square-foot production facility that it’s calling ‘Aurora Sky’. Completion of this project would mark a huge capacity increase from Aurora’s current facility, which clocks in at just 55,200 square feet.
In May, Aphria (OTCQB: APHQF) (TSX: APH) threw its hat into the ring when it announced plans to triple its production capacity as part of its four-part construction effort in Leamington, Ontario. The expansion project is on course for completion in July 2018, according to Aphria CEO Vic Neufeld. Meanwhile, Medical Marijuana (OTC: MJNA), the first publicly traded cannabis company in the United States, has continued to fortify its presence on the international cannabis scene, becoming the first company to have cannabis products subsidized by the Mexican government earlier this year.
Legalization of cannabis for recreational use is creating a huge opportunity for Licensed Producers in Canada. While quality concerns and product recalls have impacted the expansion efforts of many of the industry’s most recognizable names, the importance of consistent and dependable growing techniques has been reaffirmed. ABcann’s combination of a promising IP portfolio, a strong cash position, sizable real estate assets and a relatively low market cap – combined with a clean sheet in terms of product recalls and quality blunders – make it an intriguing investment option in the Canadian cannabis industry. Look for big moves as the company approaches ramp up of production at its new facilities in the coming months.
For more information on ABcann Global Corp. please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
440
|
Created
|
04/18/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |